Outcome of Synthetic Bone Graft GENEX in the treatment of bony defects

  • Research type

    Research Study

  • Full title

    Radiographic analysis and clinical outcomes of an absorbable calcium composite synthetic bone graft (GENEX) in the treatment of bony defects

  • IRAS ID

    288191

  • Contact name

    Bogdan Andronic Andronic

  • Contact email

    adrian.andronic@nhs.net

  • Sponsor organisation

    Hull Teaching University Hospitals

  • Duration of Study in the UK

    0 years, 4 months, 15 days

  • Research summary

    GeneX (Biocomposites Ltd., Keele, UK) is a commercially available synthetic graft which contains beta-tri-calcium phosphate and calcium sulfate. It is a biphasic absorbable, osteoconductive (scaffold) putty, which can be injected in bone defects, thereby providing support, preventing collapse, and stimulating bone regrowth.
    We propose this study to evaluate the outcomes of the effectiveness of a single synthetic calcium composite graft (GeneX) in treatment of bone defects for trauma/elective cases treated in a single Level 1 Major Trauma Centre (MTC).
    All patients who have undergone GeneX application from 2012 to 2019 would be included in the study. We expect to complete the study in 6 - 12 months post approval.

  • REC name

    North West - Greater Manchester West Research Ethics Committee

  • REC reference

    21/NW/0230

  • Date of REC Opinion

    12 Oct 2021

  • REC opinion

    Further Information Favourable Opinion